Scalable rubella production in scale-X™ bioreactor with MRC-5 cells
Process optimization and scale-up from static flask to scale-X bioreactor with 30 m² cell growth surface.
Learn moreLibrary
Discover our publications
Reconciling adherence and suspension approaches for gene therapy manufacture
Intensified and automated dual platform for increased flexibility in viral vector manufacture
Learn more
Successful process transfer of vaccine candidates in scale-X™ hydro bioreactor
Direct process reproduction from multi-layer bioreactor and roller bottles for four vaccine antigens using three different cell lines (CEF, WI-38 and Vero cells)
Learn more
Redefining virus manufacturing with the fully automated and integrated NevoLine™ Upstream platform
Discover the integrated and automated NevoLine Upstream platform. Get insight on its design aligning flexibility and productivity with various process configurations according to your process needs. Get insights on case studies for vaccine and gene therapy production.
Visit site
Capitalize on reliable operations & technologies: start-up & assistance services
Univercells Technologies provides reliable service solutions and quality support & maintenance to help you maintain performance and maximum safety of the equipment.
Download
scale-X™ hydro bioreactor for early process development
The scale-X hydro bioreactor is a small-scale, single-use, structured fixed-bed bioreactor enabling direct process transfer from existing processing technology for rapid proof of concept within a reduced footprint.
Download
Promising Vero cell growth in scale-X™ bioreactors
Case study comparing adherent Vero cell growth on microcarriers and intensified, fixed-bed scale-X bioreactors hydro (2.4 m²) and carbo (10-30 m²). Results demonstrate the scale-X bioreactors as a suitable alternative to traditional technologies.
Learn more
NevoLine™ Upstream platform: integrated and automated solution for intensified virus manufacturing
The NevoLine™ Upstream system is a high-performance and automated platform for commercial virus manufacturing. It integrates all process steps from inoculation to midstream processing to deliver a ready for downstream bulk.
Download
How one CDMO used innovative technology to overcome viral vaccine production challenges?
Discover how Ology Biosciences is leveraging Univercells Technologies’ intensified fixed-bed bioreactor and bioprocessing expertise to bring vaccine production to the next level. Get case study results and expert insights on how to find success with adherent-cell growth profiles and viral performance to produce viral vaccines using the scale-X bioreactors.
Visit site
Intensified & automated biomanufacturing technologies for gene therapies production
The scale-X™ bioreactor range and the NevoLine™ platform: integrated and automated solutions for an intensified AAV and Lentiviral vectors manufacturing.
Download
The NevoLine™ platform concept – developed by Univercells
Poster illustrates the key features, benefits and applications of the NevoLine concept with the emphasis on the first implementation of this approach – The NevoLine platform for trivalent polio vaccine (sIPV).
DownloadHomogenous HEK293 cell growth in scale-X™ bioreactor
Proof of concept for scalable adherent cell growth and adenovirus production
Learn more
scale-X™ carbo bioreactor system for rapid process development
The scale-X™ carbo system is a bench-scale automated cell culture system for expression and concentration of viral drug substance, suited for rapid process development and cost-effective clinical production.
Download
NevoLine™ sIPV platform: proof of concept – developed by Univercells
The NevoLine sIPV platform was designed and developed by Univercells as part of a $12M Grand Challenges grant awarded by the Bill & Melinda Gates Foundation. This proof of concept was developed to deliver affordable inactivated polio vaccine (sIPV) in a low footprint.
Download
Disruptive micro-facility – developed by Univercells
Poster presents the NevoLine concept to deliver affordable vaccine doses based on sIPV polio vaccine case study.
Download